Cargando…

Crisaborole for atopic dermatitis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2019
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954874/ https://www.ncbi.nlm.nih.gov/pubmed/31937994 http://dx.doi.org/10.18773/austprescr.2019.075

Ejemplares similares

Dupilumab for atopic dermatitis
Publicado: (2019)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’
por: Luger, Thomas, et al.
Publicado: (2021)

Peramivir for influenza
Publicado: (2019)

Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)

Guselkumab for plaque psoriasis
Publicado: (2019)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease
Publicado: (2019)

Avanafil for erectile dysfunction
Publicado: (2019)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Telotristat ethyl for carcinoid syndrome diarrhoea
Publicado: (2019)

Tafenoquine succinate for malaria prevention
Publicado: (2019)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Plitidepsin for multiple myeloma
Publicado: (2019)

Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

Neratinib for breast cancer
Publicado: (2019)

MYOCRISIN
Publicado: (1941)

Brolucizumab for macular degeneration
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Semaglutide for type 2 diabetes
Publicado: (2020)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ro4bnv5vpk26tef7e4b51tj7p